Recurrent Second‐Trimester Euploid Pregnancy Loss Associated With Maternal–Paternal HLA Compatibility: Review Based on a Case Report of Immune‐Mediated Failure
American Journal of Reproductive Immunology · 2026
DOI: 10.1111/aji.70217 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Reproductive Immunology, 2026. Verfasst von Sonia Gayete-Lafuente und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center For Human Reproduction (CHR), New York, New York, USA. Hauptthemen laut MEDLINE: Abortion, Habitual, HLA Antigens. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Problem Recurrent pregnancy loss (RPL) is often unexplained, and emerging evidence supports a potential alloimmune contribution in a subset of patients. Excessive maternal–paternal HLA compatibility has been proposed as a mechanism impairing maternal–fetal immune tolerance. This review, based on a representative clinical case, examines the role of HLA sharing in recurrent euploid pregnancy loss. Method of Study A narrative review of current literature on alloimmune mechanisms in RPL, including classical and non‐classical HLA pathways and KIR‐HLA interactions, was conducted. A clinical case involving recurrent second‐trimester euploid losses despite multimodal immunotherapy was used to contextualize these mechanisms.
Results
The patient experienced multiple losses of chromosomally normal fetuses despite treatment with intravenous immunoglobulin, corticosteroids, hydroxychloroquine, progesterone, aspirin, and low‐molecular‐weight heparin. HLA typing demonstrated allele sharing across four of five loci, suggesting markedly reduced immunogenetic diversity at the maternal–fetal interface. This pattern aligned with proposed mechanisms of impaired trophoblast‐immune signaling and inadequate tolerance induction.
Conclusions
Excessive maternal–paternal HLA compatibility may contribute to recurrent euploid pregnancy loss through disruption of maternal–fetal immune tolerance. This case‐based review underscores the need for individualized immunologic assessment and further research into targeted therapies for alloimmune‐mediated reproductive failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center For Human Reproduction (CHR), New York, New York, USA.
- Foundation For Reproductive Medicine (FRM), New York, New York, USA.
- Department of Obstetrics and Gynecology, Hospital Universitari de Vic, Vic, Spain.
- Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
- Laboratory of Synthetic Embryology, Rockefeller University, New York, New York, USA.
ORCID-Profile: Sonia Gayete-Lafuente, Lara Guijarro-Baude, Elizabeth Choong, David Barad, Norbert Gleicher
Zitieren
APA
Gayete-Lafuente, S., Guijarro-Baude, L., Choong, E., Barad, D., & Gleicher, N. (2026). Recurrent Second‐Trimester Euploid Pregnancy Loss Associated With Maternal–Paternal HLA Compatibility: Review Based on a Case Report of Immune‐Mediated Failure. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70217
Vancouver
Gayete-Lafuente S, Guijarro-Baude L, Choong E, Barad D, Gleicher N. Recurrent Second‐Trimester Euploid Pregnancy Loss Associated With Maternal–Paternal HLA Compatibility: Review Based on a Case Report of Immune‐Mediated Failure. American Journal of Reproductive Immunology. 2026. doi:10.1111/aji.70217
BibTeX
@article{GayeteLafuente2026,
author = {Gayete-Lafuente, Sonia and Guijarro-Baude, Lara and Choong, Elizabeth and Barad, David and Gleicher, Norbert},
title = {Recurrent Second‐Trimester Euploid Pregnancy Loss Associated With Maternal–Paternal HLA Compatibility: Review Based on a Case Report of Immune‐Mediated Failure},
journal = {American Journal of Reproductive Immunology},
year = {2026},
doi = {10.1111/aji.70217}
}
EUVIMED